全球阵发性夜间血尿症治疗市场：市场规模、份额和趋势分析（按治疗方法、地区和细分，2025-2030 年）

阵发性夜间血尿症治疗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球阵发性夜间血尿症（PNH）治疗市场规模预计到2030年将达到99.6亿美元，2025年至2030年复合年增长率为9.6%。

推动市场发展的因素有几个，包括血液和骨髓相关疾病的增加、老年人口的增加、新型治疗剂的广泛应用以及生物製药的出现。

阵发性夜间血尿症(PNH) 是一种后天性慢性血液疾病。这是一种极为罕见的疾病，北美和欧洲已报告约 8,000 至 10,000 例病例。这种危及生命的疾病常表现为血栓症形成、持续性血管内溶血和全血细胞减少的三联征。儘管关于盛行率的资讯很少，但估计 PNH 影响着全世界超过 20,000 人，年发病率约为每百万 1.3 人，盛行率约为每百万 16 人。 PNH 对男性和女性都有影响。身体症状可以出现在任何年龄，但通常在 30 至 40 岁之间出现。

包括单株抗体、重组蛋白和环肽在内的新型治疗方法在新兴市场中越来越受欢迎。但Soliris和其他候选药物的治疗费用较高，开发中地区的采用构成了障碍。预计在预测期内，输血和支持性治疗将因副作用和疗效不佳而失去动力。

阵发性夜间血尿症治疗市场：分析概述

• 据估计，美国有 5,000 至 6,000 人患有 PNH，每年报告的新病例约为 450 例。
• 由于美国治疗费用高昂、各种在研药物可能核准以及新型治疗药物的采用，美国将占据全球 PNH 治疗市场的大部分收益占有率。
• 2024 年，药物治疗占据 PNH 市场的主导地位，比重超过 85.3%。除药品外，预测期内干细胞移植领域预计也将达到两位数的成长。
• 目前，有16种产品正在进行PNH治疗的临床评估，并处于不同的开发阶段。 ALXN1210、Coversin、APL2 和 RA101495 等有前景的候选药物在获得监管部门核准后具有巨大的商业性潜力。

目录

第一章 分析方法及范围

第 2 章执行摘要

第三章阵发性夜间血尿症治疗市场：驱动因素、趋势与范围

• 市场联动展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制分析
• 商业环境分析
  • 产业分析：波特五力分析
  • PESTEL 分析

第 4 章阵发性夜间血尿症治疗市场：按治疗方法的业务分析

• 治疗方法的市场占有率（2024 年和 2030 年）
• 治疗方法仪表板
• 市场规模预测及治疗方法趋势分析（2018-2030）
• 剂量
• 干细胞移植
• 输血
• 其他类型的治疗

第五章阵发性夜间血尿症治疗市场：按地区估计和趋势分析

• 各地区市场占有率（2024 年及 2030 年）
• 市场仪表板：按地区
• 市场规模预测及趋势分析（2018-2030年）
• 北美洲
  • 按国家/地区划分（2018-2030 年）
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 按国家/地区划分（2018-2030 年）
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 挪威
  • 丹麦
  • 瑞典
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 澳洲
  • 泰国
• 拉丁美洲
  • 按国家/地区划分（2018-2030 年）
  • 巴西
  • 阿根廷
• 中东和非洲
  • 按国家/地区划分（2018-2030 年）
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第六章 竞争格局

• 参与企业概况
• 公司市场地位分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Pfizer Inc.
  • Amgen Inc.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth & Trends:

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 9.96 billion by 2030, registering a CAGR of 9.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factors such as rise in the number of blood and bone marrow related disorders, an increase in the geriatric population, wider adoption of novel therapeutics, and the emergence of biologics are driving the market.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although the information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.

Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, the high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and suboptimal efficacy.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report Highlights:

• An estimated 5,000 - 6,000 people in the U.S. suffer from PNH, with approximately 450 new cases being reported annually
• U.S. dominated the global PNH treatment market dominated with a significant revenue share in 2024 due to the high cost of treatment in the U.S., potential approval of a range of pipeline drugs, and adoption of novel therapeutics
• Treatment with medication dominated the PNH market with a share of more than 85.3% in 2024. Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
• Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development. Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
• 4.4. Medication
  • 4.4.1. Medication Market, 2018 - 2030 (USD Billion)
• 4.5. Stem Cell Transplant
  • 4.5.1. Stem Cell Transplant Market, 2018 - 2030 (USD Billion)
• 4.6. Blood Transfusion
  • 4.6.1. Blood Transfusion Market, 2018 - 2030 (USD Billion)
• 4.7. Other Treatment Types
  • 4.7.1. Other Treatment Types Market, 2018 - 2030 (USD Billion)

Chapter 5. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Regulatory Framework
    • 5.4.2.3. Competitive Insights
    • 5.4.2.4. U.S. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Regulatory Framework
    • 5.4.3.3. Competitive Insights
    • 5.4.3.4. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Regulatory Framework
    • 5.4.4.3. Competitive Insights
    • 5.4.4.4. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. Europe
  • 5.5.1. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Regulatory Framework
    • 5.5.2.3. Competitive Insights
    • 5.5.2.4. UK Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Regulatory Framework
    • 5.5.3.3. Competitive Insights
    • 5.5.3.4. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Regulatory Framework
    • 5.5.4.3. Competitive Insights
    • 5.5.4.4. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Regulatory Framework
    • 5.5.5.3. Competitive Insights
    • 5.5.5.4. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Regulatory Framework
    • 5.5.6.3. Competitive Insights
    • 5.5.6.4. Spain Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.7. Norway
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Regulatory Framework
    • 5.5.7.3. Competitive Insights
    • 5.5.7.4. Norway Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.8. Denmark
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Regulatory Framework
    • 5.5.8.3. Competitive Insights
    • 5.5.8.4. Denmark Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.9. Sweden
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Regulatory Framework
    • 5.5.9.3. Competitive Insights
    • 5.5.9.4. Sweden Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Regulatory Framework
    • 5.6.2.3. Competitive Insights
    • 5.6.2.4. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Regulatory Framework
    • 5.6.3.3. Competitive Insights
    • 5.6.3.4. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Regulatory Framework
    • 5.6.4.3. Competitive Insights
    • 5.6.4.4. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.5. South Korea
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Regulatory Framework
    • 5.6.5.3. Competitive Insights
    • 5.6.5.4. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.6. Australia
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Regulatory Framework
    • 5.6.6.3. Competitive Insights
    • 5.6.6.4. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Regulatory Framework
    • 5.6.7.3. Competitive Insights
    • 5.6.7.4. Thailand Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Latin America
  • 5.7.1. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Regulatory Framework
    • 5.7.2.3. Competitive Insights
    • 5.7.2.4. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Regulatory Framework
    • 5.7.3.3. Competitive Insights
    • 5.7.3.4. Argentina Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. MEA
  • 5.8.1. MEA Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Regulatory Framework
    • 5.8.2.3. Competitive Insights
    • 5.8.2.4. South Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Regulatory Framework
    • 5.8.3.3. Competitive Insights
    • 5.8.3.4. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Regulatory Framework
    • 5.8.4.3. Competitive Insights
    • 5.8.4.4. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Regulatory Framework
    • 5.8.5.3. Competitive Insights
    • 5.8.5.4. Kuwait Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Alexion Pharmaceuticals, Inc.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Treatment Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Apellis Pharmaceuticals
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Treatment Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Novartis AG
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Treatment Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. F. Hoffmann-La Roche Ltd
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Treatment Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Genentech, Inc.
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Treatment Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. BioCryst Pharmaceuticals, Inc.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Treatment Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. Regeneron Pharmaceuticals Inc.
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Treatment Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Sanofi
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Treatment Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Pfizer Inc.
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Treatment Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Amgen Inc.
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Treatment Benchmarking
    • 6.5.10.4. Strategic Initiatives

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global paroxysmal nocturnal hemoglobinuria treatment market, by region, 2018 - 2030 (USD Billion)
• Table 4. Global paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 5. North America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
• Table 6. North America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 7. U.S. paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 8. Canada paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 9. Mexico paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 10. Europe paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
• Table 11. Europe paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 12. UK paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 13. Germany paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 14. France paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 15. Italy paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 16. Spain paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 17. Norway paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 18. Denmark paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 19. Sweden paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 20. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
• Table 21. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 22. Japan paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 23. China paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018-2030 (USD Billion)
• Table 24. India paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 25. Australia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 26. South Korea paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 27. Thailand paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 28. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
• Table 29. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 30. Brazil paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 31. Argentina paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 32. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
• Table 33. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 34. South Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 35. Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 36. UAE paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 37. Kuwait paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Paroxysmal Nocturnal Hemoglobinuria Treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Treatment outlook (USD Billion)
• Fig. 10 Competitive landscape
• Fig. 11 Paroxysmal Nocturnal Hemoglobinuria Treatment market dynamics
• Fig. 12 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Porter's five forces analysis
• Fig. 13 Paroxysmal Nocturnal Hemoglobinuria Treatment market: PESTLE analysis
• Fig. 14 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment segment dashboard
• Fig. 15 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment market share analysis, 2024 & 2030
• Fig. 16 Medication market, 2018 - 2030 (USD Billion)
• Fig. 17 Stem cell transplant market, 2018 - 2030 (USD Billion)
• Fig. 18 Blood transfusion market, 2018 - 2030 (USD Billion)
• Fig. 19 Other treatment types market, 2018 - 2030 (USD Billion)
• Fig. 20 Paroxysmal Nocturnal Hemoglobinuria Treatment market revenue, by region
• Fig. 21 Regional marketplace: Key takeaways
• Fig. 22 North America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 23 U.S. country dynamics
• Fig. 24 U.S. paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 25 Canada country dynamics
• Fig. 26 Canada paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 27 Mexico country dynamics
• Fig. 28 Mexico paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 29 Europe paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 30 UK country dynamics
• Fig. 31 UK paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 32 Germany country dynamics
• Fig. 33 Germany paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 34 France country dynamics
• Fig. 35 France paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 36 Italy country dynamics
• Fig. 37 Italy paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 38 Spain country dynamics
• Fig. 39 Spain paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 40 Norway country dynamics
• Fig. 41 Norway paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 42 Sweden country dynamics
• Fig. 43 Sweden paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 44 Denmark country dynamics
• Fig. 45 Denmark paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 46 Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 47 Japan country dynamics
• Fig. 48 Japan paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 49 China country dynamics
• Fig. 50 China paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 51 India country dynamics
• Fig. 52 India paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 53 Australia country dynamics
• Fig. 54 Australia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 55 South Korea country dynamics
• Fig. 56 South Korea paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 57 Thailand country dynamics
• Fig. 58 Thailand paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 59 Latin America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 60 Brazil country dynamics
• Fig. 61 Brazil paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 62 Argentina country dynamics
• Fig. 63 Argentina paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 64 MEA paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 65 South Africa country dynamics
• Fig. 66 South Africa paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 67 Saudi Arabia country dynamics
• Fig. 68 Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 69 UAE country dynamics
• Fig. 70 UAE paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 71 Kuwait country dynamics
• Fig. 72 Kuwait paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
• Fig. 73 Company categorization
• Fig. 74 Company market position analysis
• Fig. 75 Strategic framework